Ocean Study Articles & Analysis
4 news found
The OCEANIC-AF (atrial fibrillation) study with asundexian is part of the Phase III OCEANIC clinical trial program enrolling more than 27,000 patients in over 40 countries Asundexian is being evaluated as a potential improved treatment option in stroke prevention and could be part of an entirely new class of treatment options in thrombosis ...
ByBayer AG
In recent studies published and reviewed in Nature, Ocean Biomedical’s Scientific Co-founder, Dr. ...
Our clear goal is to develop a new treatment option to prevent thrombotic events.” The OCEANIC Phase III clinical development program will start with two large multinational studies, OCEANIC-AF and OCEANIC-STROKE, expected to enroll up to 30,000 patients in over 40 countries. ...
ByBayer AG
We are delighted to highlight two studies produced by the Blue Ocean Robotics team together with our product specialist, Britta Geleijns. ...